Rocket Pharmaceuticals, Inc. (RCKT)
2.18
-0.18
(-7.63%)
USD |
NASDAQ |
Oct 16, 16:00
2.21
+0.03
(+1.38%)
After-Hours: 20:00
Rocket Pharmaceuticals Research and Development Expense (Annual) : 135.71M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 135.71M |
| December 31, 2024 | 165.22M |
| December 31, 2023 | 180.97M |
| December 31, 2022 | 161.53M |
| December 31, 2021 | 120.20M |
| December 31, 2020 | 108.84M |
| December 31, 2019 | 59.40M |
| Date | Value |
|---|---|
| December 31, 2018 | 53.27M |
| December 31, 2017 | 14.92M |
| December 31, 2016 | 31.98M |
| December 31, 2015 | 12.55M |
| December 31, 2014 | 8.861M |
| December 31, 2013 | 5.33M |
| December 31, 2012 | 3.542M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Sarepta Therapeutics, Inc. | 1.493B |
| Intellia Therapeutics, Inc. | 379.09M |
| Beam Therapeutics, Inc. | 409.62M |
| Arrowhead Pharmaceuticals, Inc. | 585.26M |
| Oncolytics Biotech, Inc. | 13.31M |